The Food and Drug Administration Saturday issued an emergency use authorization to Yale School of Public Health for a new test to detect SARS-CoV-2 in saliva, which does not require saliva collection tubes containing preservatives or specialized equipment for nucleic acid extraction. 

“Providing this type of flexibility for processing saliva samples to test for COVID-19 infection is groundbreaking in terms of efficiency and avoiding shortages of crucial test components like reagents,” said FDA Commissioner Stephen Hahn, M.D.

The SalivaDirect test is authorized for use by Yale-designated laboratories that are certified under the Clinical Laboratory Improvement Amendments of 1988 and meet requirements to perform high complexity tests.

On Friday, FDA listed personal protective equipment, testing supplies and other medical devices in shortage or discontinued. The Coronavirus Aid, Relief, and Economic Security requires manufacturers to notify FDA when a manufacturing discontinuance or interruption is likely to disrupt the U.S. supply of certain devices during a public health emergency. The agency plans to update the lists as the pandemic evolves.

Related News Articles

Headline
Adults age 65 and older are encouraged to receive an updated dosage of the COVID-19 vaccine, the Centers for Disease Control and Prevention announced April 25…
Headline
Paxlovid may no longer be distributed with an emergency use label after March 8, the Food and Drug Administration announced. Providers may dispense unexpired…
Headline
The Food and Drug Administration’s independent Nonprescription Drugs Advisory Committee Sept. 12 by unanimous vote declared oral phenylephrine…
Headline
The Senate Health, Education, Labor and Pensions Committee today 17-3 to pass as amended the Pandemic and All-Hazards Preparedness and Response Act (S. 2333),…
Headline
The Food and Drug Administration’s vaccine advisory committee June 15 voted unanimously to recommend updating the current COVID-19 vaccine composition for…
Headline
The first data on the safety of a third mRNA COVID-19 vaccine dose among young children show that a third dose is safe for children ages 6 months to 5 years…